ES2477940T3 - Imidazoles condensados y composiciones que los incluyen para el tratamiento de enfermedades parasitarias tales como por ejemplo malaria - Google Patents

Imidazoles condensados y composiciones que los incluyen para el tratamiento de enfermedades parasitarias tales como por ejemplo malaria Download PDF

Info

Publication number
ES2477940T3
ES2477940T3 ES10733107.6T ES10733107T ES2477940T3 ES 2477940 T3 ES2477940 T3 ES 2477940T3 ES 10733107 T ES10733107 T ES 10733107T ES 2477940 T3 ES2477940 T3 ES 2477940T3
Authority
ES
Spain
Prior art keywords
malaria
compositions
treatment
parasitic diseases
condensed imidazoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10733107.6T
Other languages
English (en)
Inventor
Arnab K. Chatterjee
Advait Nagle
Tao Wu
David Tully
Kelli L. Kuhen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2477940(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by IRM LLC filed Critical IRM LLC
Application granted granted Critical
Publication of ES2477940T3 publication Critical patent/ES2477940T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de Fórmula Id: en los que: R1 es -NH2; R2 y R3 se seleccionan independientemente entre hidrógeno y metilo; R4 y R5 se seleccionan independientemente entre hidrógeno y metilo; R6 es fenilo sustituido con flúor; y R8 es un fenilo sustituido con de 1 a 2 radicales seleccionados independientemente entre cloro y flúor; o una sal farmacéuticamente aceptable de los mismos.

Description

imagen1

Claims (1)

  1. imagen1
ES10733107.6T 2009-07-09 2010-07-09 Imidazoles condensados y composiciones que los incluyen para el tratamiento de enfermedades parasitarias tales como por ejemplo malaria Active ES2477940T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US224433P 2000-08-10
US22443309P 2009-07-09 2009-07-09
PCT/US2010/041626 WO2011006143A2 (en) 2009-07-09 2010-07-09 Compounds and compositions for the treatment of parasitic diseases

Publications (1)

Publication Number Publication Date
ES2477940T3 true ES2477940T3 (es) 2014-07-18

Family

ID=42727573

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10733107.6T Active ES2477940T3 (es) 2009-07-09 2010-07-09 Imidazoles condensados y composiciones que los incluyen para el tratamiento de enfermedades parasitarias tales como por ejemplo malaria
ES14156496.3T Active ES2574529T3 (es) 2009-07-09 2010-07-09 Imidazo[1,2a]pirazinas y composiciones que las incluyen para el tratamiento de enfermedades parasíticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14156496.3T Active ES2574529T3 (es) 2009-07-09 2010-07-09 Imidazo[1,2a]pirazinas y composiciones que las incluyen para el tratamiento de enfermedades parasíticas

Country Status (38)

Country Link
US (3) US8557801B2 (es)
EP (2) EP2737927B1 (es)
JP (1) JP5432376B2 (es)
KR (1) KR101378666B1 (es)
CN (1) CN102471341B (es)
AR (1) AR077463A1 (es)
AU (1) AU2010271247B2 (es)
BR (1) BR112012000413B1 (es)
CA (1) CA2767664C (es)
CL (1) CL2012000042A1 (es)
CO (1) CO6491060A2 (es)
CR (1) CR20120008A (es)
CU (1) CU24155B1 (es)
DK (1) DK2451814T3 (es)
EA (1) EA019655B1 (es)
EC (1) ECSP12011585A (es)
ES (2) ES2477940T3 (es)
GT (1) GT201200004A (es)
HK (1) HK1164304A1 (es)
HN (1) HN2012000023A (es)
HR (1) HRP20140641T1 (es)
IL (1) IL217384A (es)
JO (1) JO3156B1 (es)
MA (1) MA33419B1 (es)
MX (1) MX2012000389A (es)
MY (1) MY157238A (es)
NZ (1) NZ597275A (es)
PE (1) PE20130399A1 (es)
PL (1) PL2451814T3 (es)
PT (1) PT2451814E (es)
SG (1) SG176938A1 (es)
SI (1) SI2451814T1 (es)
SM (1) SMT201400096B (es)
TN (1) TN2011000647A1 (es)
TW (1) TWI421252B (es)
UA (1) UA103930C2 (es)
UY (1) UY32776A (es)
WO (1) WO2011006143A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2920169A1 (en) 2012-11-14 2015-09-23 F. Hoffmann-La Roche AG Imidazopyridine derivatives
PT2925757T (pt) * 2012-11-19 2018-01-09 Novartis Ag Compostos e composições para o tratamento de doenças parasitárias
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US20150291598A1 (en) * 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN103126782B (zh) * 2013-02-26 2016-06-29 内蒙古农牧业科学院 一种寄生病的治疗方法
HUE040254T2 (hu) * 2013-12-19 2019-02-28 Novartis Ag Protozoa proteaszóma inhibitor [1,2,4]triazolo[1,5-a]pirimidinszármazékok paraziták által okozott betegségek, például leishmaniasis kezelésére
ES2757052T3 (es) 2015-07-31 2020-04-28 Merck Patent Gmbh Derivados heterocíclicos bicíclicos
PE20190800A1 (es) 2016-08-15 2019-06-10 Bayer Cropscience Ag Derivados del heterociclo biciclico condensado como agentes de control de plagas
TWI791515B (zh) * 2017-04-24 2023-02-11 瑞士商諾華公司 治療療法
FI3652178T3 (fi) 2017-07-14 2024-03-19 Hoffmann La Roche Bisyklisiä ketoniyhdisteitä ja niiden käyttömenetelmiä
EP3692052A4 (en) * 2017-10-04 2021-03-17 Dana Farber Cancer Institute, Inc. INHIBITION BY SMALL MOLECULES OF THE TRANSCRIPTION FACTOR SALL4 AND ITS USES
WO2022049548A1 (en) 2020-09-04 2022-03-10 Novartis Ag Kaf156 combinations and methods for the treatment of malaria
WO2023168107A2 (en) * 2022-03-04 2023-09-07 University Of Central Florida Research Foundation, Inc. Compounds and compositions for anitmalarial therapeutic and prophylactic use
CN114569711B (zh) * 2022-03-24 2024-04-19 安徽医科大学 一种预防弓形虫病的ME49Δcdpk3减毒活疫苗及其制备方法和应用
WO2024006971A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
WO2024006970A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
WO2024006974A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK476885D0 (da) 1985-10-17 1985-10-17 Ferrosan As Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
CZ20004568A3 (cs) 1998-06-12 2001-11-14 Societe De Conseils De Recherches Et D'application Sloučenina imidazolylu, farmaceutický prostředek a způsob výroby
FR2780974B1 (fr) 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
DE69915514T2 (de) * 1998-12-31 2005-01-05 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Prenyltransferase-inhibitoren
RU2298417C2 (ru) 1999-11-09 2007-05-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) Продукт, включающий ингибитор трансдукции сигналов гетеротримерных протеинов g в комбинации с другим цитостатическим средством, для терапевтического применения при лечении рака
FR2803525B1 (fr) 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
WO2002010140A2 (en) 2000-08-01 2002-02-07 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Imidazolyl derivatives
CN1237060C (zh) * 2001-01-02 2006-01-18 弗·哈夫曼-拉罗切有限公司 用作α1A/B肾上腺素能受体拮抗剂的喹唑酮衍生物
FR2825278A1 (fr) 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
DE60316416T2 (de) 2002-03-25 2008-06-26 Merck & Co., Inc. Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
AU2003274565A1 (en) 2002-09-27 2004-04-19 Centre National De Recherche Scientifique Composition for the treatment of nasopharyngeal carcinoma and use thereof
WO2004058266A1 (en) * 2002-12-20 2004-07-15 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1572682A4 (en) 2002-12-20 2008-01-23 Pharmacia Corp ACYCLIC PYRAZOLE COMPOUNDS
US7504501B2 (en) * 2003-03-06 2009-03-17 Merial Limited Antiprotozoal imidazopyridine compounds
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
EP1624874B1 (en) 2003-05-14 2009-11-04 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2867778B1 (fr) * 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
CA2617715A1 (en) 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
EP2010180A4 (en) 2006-04-21 2010-10-13 Glaxosmithkline Llc IL-8 RECEPTOR ANTAGONISTS
US20120142623A1 (en) 2006-07-07 2012-06-07 Michael Lagunoff Compositions And Methods For Predicting Inhibitors Of Protein Targets
TW200808056A (en) * 2006-07-26 2008-02-01 Compal Communications Inc Rear projection display system
CN101622001A (zh) 2007-01-26 2010-01-06 Irm责任有限公司 作为激酶抑制剂用于治疗疟原虫相关疾病的嘌呤化合物和组合物
US20080242862A1 (en) * 2007-03-27 2008-10-02 Calderwood David J Novel imidazo based heterocycles
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
CN101357922B (zh) 2007-08-02 2011-05-18 山东轩竹医药科技有限公司 新的dpp-iv抑制剂
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
CN102131805A (zh) 2008-06-20 2011-07-20 百时美施贵宝公司 用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物

Also Published As

Publication number Publication date
EA019655B1 (ru) 2014-05-30
TWI421252B (zh) 2014-01-01
BR112012000413A2 (pt) 2020-08-11
SMT201400096B (it) 2014-09-08
CA2767664A1 (en) 2011-01-13
CR20120008A (es) 2012-03-12
US9469645B2 (en) 2016-10-18
EP2451814B1 (en) 2014-04-09
US20110059934A1 (en) 2011-03-10
US9963454B2 (en) 2018-05-08
ECSP12011585A (es) 2012-02-29
UY32776A (es) 2011-02-28
MY157238A (en) 2016-05-13
PE20130399A1 (es) 2013-04-06
KR20120047939A (ko) 2012-05-14
AU2010271247A1 (en) 2012-01-19
CL2012000042A1 (es) 2012-12-21
HK1164304A1 (en) 2012-09-21
CU20120002A7 (es) 2012-06-21
NZ597275A (en) 2013-05-31
UA103930C2 (ru) 2013-12-10
TN2011000647A1 (en) 2013-05-24
BR112012000413B1 (pt) 2022-02-15
JP5432376B2 (ja) 2014-03-05
CA2767664C (en) 2013-12-10
MX2012000389A (es) 2012-03-07
HN2012000023A (es) 2014-08-18
HRP20140641T1 (hr) 2014-09-26
EP2737927A1 (en) 2014-06-04
SI2451814T1 (sl) 2014-08-29
SG176938A1 (en) 2012-01-30
JO3156B1 (ar) 2017-09-20
EP2737927B1 (en) 2016-03-30
TW201105675A (en) 2011-02-16
US20130281403A1 (en) 2013-10-24
WO2011006143A2 (en) 2011-01-13
JP2012532890A (ja) 2012-12-20
US8557801B2 (en) 2013-10-15
WO2011006143A3 (en) 2011-06-09
EP2451814A2 (en) 2012-05-16
IL217384A0 (en) 2012-02-29
ES2574529T3 (es) 2016-06-20
PT2451814E (pt) 2014-07-16
GT201200004A (es) 2014-03-27
DK2451814T3 (da) 2014-07-14
PL2451814T3 (pl) 2014-09-30
US20160108051A1 (en) 2016-04-21
CO6491060A2 (es) 2012-07-31
CN102471341A (zh) 2012-05-23
CN102471341B (zh) 2014-07-02
MA33419B1 (fr) 2012-07-03
AR077463A1 (es) 2011-08-31
EA201200098A1 (ru) 2012-07-30
KR101378666B1 (ko) 2014-03-26
IL217384A (en) 2015-07-30
CU24155B1 (es) 2016-03-31
AU2010271247B2 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
ES2477940T3 (es) Imidazoles condensados y composiciones que los incluyen para el tratamiento de enfermedades parasitarias tales como por ejemplo malaria
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
TN2018000043A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
CO7160015A2 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
CO6470866A2 (es) Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos.
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
AR078495A1 (es) Compuestos policiclicos como antagonistas del receptor de acido lisofosfatidico
EA201391158A1 (ru) Диаминиевые соли фенотиазина и их применение
UY32391A (es) Compuestos amino-heterocíclicos
UY32490A (es) Inhibidores de beta-secretasa
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
EA201490357A1 (ru) Индазолы
SV2009003411A (es) Compuestos de amino-heterociclico
UY33779A (es) ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
UY32483A (es) Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
PE20140604A1 (es) Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.